Pyc Therapeutics Ltd has released a press release.
Successful Dose Response & Toxicity Studies in Lead Program
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Story so far
Earlier from PYC Therapeutics
- S&P DJI Announces June 2020 Quarterly Rebalance
- March 2020 Quarterly Activities and Cash Flow Report
- Successful Efficacy Result on Path to First in Human Studies
- Investor Presentation - February 2020
- CEO Appointment and Establishment of US Office
Later from PYC Therapeutics
- June 2020 Quarterly Activity Report and Cashflow
- Shareholder Update - Forward View 2020 Milestones
- Executive re-structure across global operations
- Appendix 4E Preliminary Final Report
- Creation of Novel Gene Therapy Delivery Technology
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics